Saw Palmetto
10 benefits mapped to clinical evidence across supplements.
Dose per serving from products
1,524 products in our catalogue print how much Saw Palmetto a serving holds.
Most common: 250 mg to 500 mg, 43% of 1,524 products.
| Dose per serving | Products |
|---|---|
| 10 mg or less | 39 |
| 10 mg to 25 mg | 64 |
| 25 mg to 50 mg | 77 |
| 50 mg to 100 mg | 194 |
| 100 mg to 250 mg | 326 |
| 250 mg to 500 mg | 651 |
| 500 mg to 1 g | 143 |
| over 1 g | 30 |
Dose per serving from research
48 study groups in 37 studies say how much Saw Palmetto participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mg to 500 mg, 88% of 48 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mg to 250 mg | 5 |
| 250 mg to 500 mg | 42 |
| over 500 mg | 1 |
Benefit Evidence
Inflammation ↓, markers
Inflammation −53%, immune cells
Inflammation ↓, symptoms
Inflammation ↓, markers
Inflammation −53%, immune cells
Inflammation ↓, symptoms
Research sources
Urinary comfort (49)
- Chronic bacterial prostatitis: efficacy of short-lasting antibiotic therapy with prulifloxacin (Unidrox®) in association with saw palmetto extract, lactobacillus sporogens and arbutin (Lactorepens®)
PubMed ID: 25038794
Large randomized study: adding a multi-ingredient supplement containing Serenoa to antibiotics markedly reduced prostatitis symptoms and recurrences.
- Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia
PubMed ID: 10751856
Small randomized trial reported decreased percent epithelium and increased atrophy in transition zone with saw palmetto → histologic support for tissue-level prostate effects.
- Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms
PubMed ID: 11744467
6-month randomized placebo-controlled trial showed modest but statistically significant IPSS improvement vs placebo (no flow benefit).
- Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens
PubMed ID: 11337315
Randomized tissue study showed ~32% reduction in intraprostatic DHT → a plausible local mechanism for prostate symptom benefit.
- Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism
PubMed ID: 12385921
Six-month randomized study found significant changes in nuclear/DNA architecture of prostate epithelial cells after Serenoa repens → molecular prostate effects.
- Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study
PubMed ID: 12074791
12-month randomized trial found Permixon produced symptom improvement equivalent to tamsulosin → strong evidence for symptomatic prostate comfort.
- [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study]
PubMed ID: 12189744
Duplicate report of the 12-month Permixon vs tamsulosin trial showing equivalent symptom relief → strong support.
- The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens
PubMed ID: 12665049
6-month randomized dose-comparison showed significant IPSS and objective urinary improvements with Serenoa repens extract.
- Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis
PubMed ID: 15149751
Subset analysis in severe BPH showed Permixon reduced total and irritative IPSS more than tamsulosin → supports symptomatic benefit in severe cases.
- [Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis]
PubMed ID: 15373174
Subset PERMAL analysis showed modest superiority of Permixon vs tamsulosin for irritative LUTS and total IPSS in severe BPH patients.
- [Morphological changes in prostatic tissue of patients with benign prostatic hyperplasia treated with permixon]
PubMed ID: 15560155
Tissue-level effects (reduced proliferation/inflammation) support biological basis for prostate symptom improvement.
- [Efficacy of pretreatment with Serenoa repens on bleeding associated with transurethral resection of prostate]
PubMed ID: 15195032
Pretreatment lowered blood loss and shortened catheter time for TURP, suggesting clinical periprocedural prostate benefits.
- Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin
PubMed ID: 16618015
Sabal+urtica produced reductions in I-PSS comparable to tamsulosin over 60 weeks; flow improvements implied though not primary.
- Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China
PubMed ID: 18082217
Chinese double-blind RCT (12 weeks) showed Qmax increase (~+2.33 ml/s) and higher symptomatic responder rate vs placebo.
- Serenoa repens (Permixon®) reduces intra- and postoperative complications of surgical treatments of benign prostatic hyperplasia
PubMed ID: 20940691
Two months pre-op saw palmetto reduced complications, transfusions and shortened operations/hospital stay — meaningful prostate surgical benefit.
- Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?
PubMed ID: 24450252
Randomized comparison: Serenoa repens alone worked about as well as tamsulosin for BPH symptoms (no added benefit when combined).
- A prospective interventional study in chronic prostatitis with emphasis to clinical features
PubMed ID: 25194085
Randomized study suggested symptom improvement when phytotherapy was added to antibiotics, but data and phytotherapy composition were unclear.
- Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study
PubMed ID: 25614155
Addition of Serenoa to tamsulosin produced a significant improvement in storage subscore (irritative/bladder symptoms).
- [Efficacy and safety of № I Empirical Prescription for Chronic Prostatitis in the treatment of type Ⅲ refractory chronic prostatitis]
PubMed ID: 30173449
Small RCT: modest improvements in NIH-CPSI and Qmax with saw palmetto.
- The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study
PubMed ID: 30027406
Biopsy study: hexanic extract reduced prostate inflammation — biologic basis for prostate symptom improvement.
- Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
PubMed ID: 30880074
Large 24-week double-blind RCT: saw palmetto extract improved IPSS, Qmax and QoL vs placebo.
- [A comparative analysis of the effectiveness of serenoa repens and serenoa repens in combination with urtica dioiccus for lower urinary symptoms suggestive of benign prostatic hyperplasia associated with chronic inflammation in prostate tissue]
PubMed ID: 31184016
Open randomized study: Serenoa+nettle worked better than Serenoa alone for urinary symptoms in BPH with inflammation.
- The efficacy and safety of Serenoa repens extract for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized, double-blind, placebo-controlled trial
PubMed ID: 33452912
Well-powered double-blind RCT: Serenoa repens extract substantially reduced NIH-CPSI total, pain and urinary scores vs placebo.
- Beneficial Effects of Saw Palmetto Fruit Extract on Urinary Symptoms in Japanese Female Subjects by a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
PubMed ID: 35334848
In older women, saw palmetto reduced daytime urinary frequency, indicating improved bladder comfort.
- Beneficial effects of saw palmetto (Serenoa repens) fruit extract on the urinary symptoms of healthy Japanese adults with possible lower urinary tract symptoms: A randomized, double-blind, placebo-controlled study
PubMed ID: 39042923
Older-adult RCT: 320 mg saw palmetto reduced daytime urination frequency and related bother.
- Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study
PubMed ID: 41098072
12-month trial in men with BPH showed statistically significant additional improvement in IPSS when saw palmetto was added to alfuzosin, directly supporting prostate symptom comfort.
- Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH)
PubMed ID: 12092634
Multi-ingredient supplement (includes saw palmetto) produced marked nocturia reduction vs placebo, but effect cannot be solely attributed to saw palmetto.
- Effects of Difaprost® on voiding dysfunction, histology and inflammation markers in patients with benign prostatic hyperplasia who are candidates for surgical treatment
PubMed ID: 24988203
Small randomized pre-surgery trial with Serenoa-containing product showed trends to improved post-void residual and less histologic edema.
- A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency
PubMed ID: 32620155
Sterol-enriched saw palmetto significantly increased Qmax vs conventional and placebo.
- Serenoa repens associated with selenium and lycopene extract and bromelain and methylsulfonylmethane extract are able to improve the efficacy of levofloxacin in chronic bacterial prostatitis patients
PubMed ID: 27711089
Randomized study: supplement with Serenoa added to levofloxacin improved chronic bacterial prostatitis symptoms and recurrence.
- The Use of a Combination of Vaccinium Macracarpon, Lycium barbarum L. and Probiotics (Bifiprost®) for the Prevention of Chronic Bacterial Prostatitis: A Double-Blind Randomized Study
PubMed ID: 31527377
Adding botanical/probiotic to Serenoa reduced recurrence of bacterial prostatitis and improved NIH-CPSI at later follow-up.
- Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study
PubMed ID: 19181486
Combination with other herbal extracts plus antibiotic greatly increased short-term symptom relief and reduced recurrences in bacterial prostatitis.
- [Approaches to raising efficacy of treatment of patients with chronic prostatitis associated with intracellular infections]
PubMed ID: 21427997
Small trial in infectious prostatitis: adding product containing S. repens to antibiotics improved bacterial clearance and symptoms vs antibiotic alone (multi-ingredient).
- Flower Pollen Extract in Association with Vitamins (Deprox 500®) Versus Serenoa repens in Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Comparative Analysis of Two Different Treatments
PubMed ID: 30488800
Small trial: saw palmetto helped prostatitis/urinary scores but was outperformed by pollen+vitamin product.
- Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study
PubMed ID: 20332612
Triple formulation gave much larger reductions in NIH-CPSI and IPSS than S. repens alone in chronic prostatitis, improving urinary tract comfort.
- A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy
PubMed ID: 23642948
Multi-herb capsule including Serenoa reduced nighttime urinary frequency substantially vs placebo over 3 months.
- Effects of Serenoa repens, selenium and lycopene (Profluss®) on chronic inflammation associated with benign prostatic hyperplasia: results of "FLOG" (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study
PubMed ID: 23683667
Supplement containing Serenoa repens associated with decreased prostate inflammation markers and immune cells.
- Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial)
PubMed ID: 25154739
Large double-blind randomized trial: Serenoa-containing supplement plus tamsulosin improved IPSS/PVR/Qmax more than monotherapies.
- Serenoa repens + selenium + lycopene vs tadalafil 5 mg for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: a Phase IV, non-inferiority, open-label, clinical study (SPRITE study)
PubMed ID: 29569389
Large non-inferiority trial: Serenoa-containing supplement (with selenium/lycopene) performed similarly to tadalafil for urinary symptoms and flow.
- Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome
PubMed ID: 10971268
Saw palmetto+nettle combination increased maximum urinary flow similarly to finasteride in subgroup analysis (combination product).
- Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms--a placebo-controlled, double-blind, multicenter trial
PubMed ID: 15928959
Sabal (saw palmetto) + nettle capsule modestly improved I-PSS vs placebo over 24 weeks.
- [Efficacy of a combined Sabal-urtica preparation in the symptomatic treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study]
PubMed ID: 16261945
Re-analysis found significant improvement in urinary frequency and urgency (bladder irritative symptoms) with sabal-urtica product vs placebo.
- [Combined extract of Sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in double blind, placebo-controlled trial]
PubMed ID: 16708583
Multicenter double-blind trial of sabal+nettle showed improved I-PSS and QoL vs placebo.
- Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms--long-term follow-up of a placebo-controlled, double-blind, multicenter trial
PubMed ID: 18038253
Open 96-week follow-up reported peak and average urinary flow increases (~+19%).
- Fixed-dose combination PRO 160/120 of sabal and urtica extracts improves nocturia in men with LUTS suggestive of BPH: re-evaluation of four controlled clinical studies
PubMed ID: 24938176
Pooled RCTs of saw palmetto+nettle showed a statistically significant and clinically meaningful reduction in nocturnal voids.
- Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients
PubMed ID: 1281103
Small study in BPH patients found reduced nuclear estrogen and progesterone receptors in prostate tissue after Serenoa repens → possible tissue-level hormonal modulation relevant to prostate comfort.
- Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia
PubMed ID: 7537488
Short 3-week randomized study found modest symptomatic benefit versus alfuzosin (but inferior to the drug), suggesting some symptomatic effect.
- Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients
PubMed ID: 8876706
Large 6-month RCT (Permixon) showed clinically meaningful IPSS improvement comparable to finasteride → strong clinical support for prostate symptom relief.
- Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens
PubMed ID: 10915398
Dose-comparison trial in BPH patients reported symptomatic and objective urinary improvements over 3 months with saw palmetto extract (no placebo group).
Healthy aging (9)
- A detailed safety assessment of a saw palmetto extract
PubMed ID: 18534327
One-year randomized safety data showed no major harms, supporting tolerability in older men.
- The Safety and Efficacy of a Novel Saw Palmetto (Serenoa repens) Extract for Promoting Hair Growth in Adults With Self-Perceived Thinning Hair: 180-Day Results
PubMed ID: 41652806
Demonstrated reversal of age‑related hair thinning metrics over 180 days, supporting age-related cosmetic comfort.
- Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study
PubMed ID: 41098072
Addresses BPH symptoms that commonly arise with aging; showed a modest additive benefit when combined with alfuzosin.
- Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
PubMed ID: 30880074
Large RCT in men with LUTS reported QoL and urinary improvements over 24 weeks, reflecting improved comfort in an aging population.
- Safety and toxicity of saw palmetto in the CAMUS trial
PubMed ID: 23063633
CAMUS safety data supports tolerability of saw palmetto in an older male population at escalating doses.
- Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis
PubMed ID: 15149751
Subset analysis in severe BPH showed greater symptom reduction with Permixon vs tamsulosin, relevant to aging men with severe symptoms.
- The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens
PubMed ID: 12665049
6-month randomized study showed symptomatic and objective urinary improvements that may improve aging-associated urinary comfort.
- Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study
PubMed ID: 12074791
12-month trial showing sustained symptom improvement vs baseline suggests better urinary comfort with aging-related BPH symptoms.
- Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients
PubMed ID: 8876706
Large trial demonstrating symptomatic improvement over 6 months supports comfort during aging in men with BPH.
Inflammation (6)
- [A comparative analysis of the effectiveness of serenoa repens and serenoa repens in combination with urtica dioiccus for lower urinary symptoms suggestive of benign prostatic hyperplasia associated with chronic inflammation in prostate tissue]
PubMed ID: 31184016
Open randomized study reported reduced prostatic inflammation with Serenoa+Urtica vs Serenoa alone.
- Effects of Serenoa repens, selenium and lycopene (Profluss®) on chronic inflammation associated with benign prostatic hyperplasia: results of "FLOG" (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study
PubMed ID: 23683667
Multicenter randomized data showed decreased prostate inflammation extent and reduced immune-cell densities with supplement containing Serenoa repens.
- Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia
PubMed ID: 26306400
Hexanic extract modulated multiple prostate inflammation mRNA/protein biomarkers vs tamsulosin.
- The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study
PubMed ID: 30027406
Randomized biopsy study: hexanic saw palmetto extract significantly reduced prostate inflammation grades and immune markers.
- Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study
PubMed ID: 20332612
Triple formulation reduced WBC/PSA and produced larger symptom reductions in chronic prostatitis compared with S. repens alone, suggesting anti-inflammatory effects in that combo.
- [Morphological changes in prostatic tissue of patients with benign prostatic hyperplasia treated with permixon]
PubMed ID: 15560155
Permixon reduced prostate tissue inflammation by ~53% and decreased epithelial proliferative activity in men with BPH (direct histologic evidence).
Wellbeing (4)
- Safety and toxicity of saw palmetto in the CAMUS trial
PubMed ID: 23063633
Large CAMUS safety analysis concluded no important toxicities up to high doses over 18 months.
- Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients
PubMed ID: 8876706
Large RCT found clinically meaningful symptom benefit with good tolerability, supporting overall wellbeing in BPH patients.
- An improvement in sexual function is related to better quality of life, regardless of urinary function improvement: results from the IDIProst® Gold Study
PubMed ID: 24399119
Multi-ingredient product including S. repens improved IPSS, erectile function and SF-36 QoL over 3 months.
- A detailed safety assessment of a saw palmetto extract
PubMed ID: 18534327
One-year randomized safety trial found no major harms, supporting general overall-wellness/safety profile.
Fertility (4)
- Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study
PubMed ID: 19181486
Adding S. repens with other herbs to antibiotics greatly increased short-term symptom relief and reduced recurrences in bacterial prostatitis.
- [Approaches to raising efficacy of treatment of patients with chronic prostatitis associated with intracellular infections]
PubMed ID: 21427997
Small RCT in infectious prostatitis: indigal plus (contains S. repens) improved bacterial clearance and symptoms vs antibiotic alone.
- Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study
PubMed ID: 20332612
Profluss (S. repens + selenium + lycopene) produced larger NIH-CPSI/IPSS improvements and decreased PSA/WBC in chronic prostatitis, which can support reproductive tract health.
- Multi-pharmacological treatment for young subfertile males with chronic prostatitis/chronic pelvic pain syndrome
PubMed ID: 39505516
In subfertile men with prostatitis, combination therapies including Serenoa improved sperm quality measures and prostatitis symptoms; attribution to Serenoa is confounded but supportive.
Hair growth (4)
- The Safety and Efficacy of a Novel Saw Palmetto (Serenoa repens) Extract for Promoting Hair Growth in Adults With Self-Perceived Thinning Hair: 180-Day Results
PubMed ID: 41652806
180-day randomized, double-blind, placebo-controlled trial showed large, statistically significant increases in hair count and thickness attributable to the saw palmetto fatty-acid extract.
- Impact of a Novel Dietary Supplement on Efficacy of Pharmacological Treatments for Androgenic Alopecia: A Real-Life, Multicenter, Randomized, Assessor-Blinded Trial on 225 Subjects
PubMed ID: 40853071
Multicenter randomized trial: supplement containing Serenoa added to standard hair drugs increased 'much improved' responder rate.
- Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study
PubMed ID: 23298508
Open-label 2-year study: ~38% of men improved with S. repens vs 68% with finasteride; indicates modest hair-growth effect though study design limits confidence.
- The Safety and Efficacy of a Proprietary Bioactive Fatty Acids Extract From Saw Palmetto (Serenoa repens) for Promoting Hair Growth and Reducing Hair Loss in Adults With Self-Perceived Thinning Hair: 90-Day Results
PubMed ID: 41319217
Double-blind placebo-controlled 90-day trial: oral saw palmetto fatty-acid extract significantly increased terminal/total hair counts and reduced shedding.
Scalp health (3)
- The Safety and Efficacy of a Novel Saw Palmetto (Serenoa repens) Extract for Promoting Hair Growth in Adults With Self-Perceived Thinning Hair: 180-Day Results
PubMed ID: 41652806
Marked increases in terminal hair count and hair thickness imply improved scalp/follicle condition in the RCT.
- The Safety and Efficacy of a Proprietary Bioactive Fatty Acids Extract From Saw Palmetto (Serenoa repens) for Promoting Hair Growth and Reducing Hair Loss in Adults With Self-Perceived Thinning Hair: 90-Day Results
PubMed ID: 41319217
Objective increases in hair counts and decreased shedding indicate improved scalp/hair environment with oral saw palmetto extract.
- Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study
PubMed ID: 23298508
Reported hair growth concentrated at the vertex; some scalp-targeted benefit observed though non-blinded design limits certainty.
Sexual wellness (2)
- An improvement in sexual function is related to better quality of life, regardless of urinary function improvement: results from the IDIProst® Gold Study
PubMed ID: 24399119
Multi-ingredient product including S. repens improved IIEF-5 erectile-function scores more than S. repens alone over 3 months.
- Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome
PubMed ID: 10971268
Saw palmetto+nettle combo had similar efficacy to finasteride but fewer sexual side effects → supports preserved/enhanced sexual function relative to finasteride (combination context).
Hormone balance (2)
- Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens
PubMed ID: 11337315
Intraprostatic DHT reduction (~32%) indicates local modulation of androgen action, which may contribute to hormone-related symptom relief in the prostate.
- Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers
PubMed ID: 7805711
Permixon produced no change in serum DHT or testosterone in controlled study, supporting that saw palmetto alone does not markedly disrupt systemic male hormones.
Skin health (1)
- The Safety and Efficacy of a Proprietary Bioactive Fatty Acids Extract From Saw Palmetto (Serenoa repens) for Promoting Hair Growth and Reducing Hair Loss in Adults With Self-Perceived Thinning Hair: 90-Day Results
PubMed ID: 41319217
Oral saw palmetto fatty-acid extract increased hair counts and reduced shedding, supporting a skin/hair health indication.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Saw Palmetto
Search all2971 products whose verified label declares Saw Palmetto — not every bottle that mentions it in a title.